ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 148 filers reported holding ARCUS BIOSCIENCES INC in Q4 2021. The put-call ratio across all filers is 1.22 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246,489 | +6.1% | 13,732 | +20.0% | 0.00% | 0.0% |
| Q2 2023 | $232,407 | +12.9% | 11,443 | +1.4% | 0.00% | 0.0% |
| Q1 2023 | $205,802 | -12.7% | 11,283 | -1.0% | 0.00% | 0.0% |
| Q4 2022 | $235,628 | -21.2% | 11,394 | -0.4% | 0.00% | -50.0% |
| Q3 2022 | $299,000 | -0.7% | 11,444 | -3.5% | 0.00% | 0.0% |
| Q2 2022 | $301,000 | -22.6% | 11,859 | -3.7% | 0.00% | 0.0% |
| Q1 2022 | $389,000 | -23.4% | 12,310 | -1.9% | 0.00% | 0.0% |
| Q4 2021 | $508,000 | +16.5% | 12,548 | +0.4% | 0.00% | 0.0% |
| Q3 2021 | $436,000 | +25.3% | 12,504 | -1.4% | 0.00% | 0.0% |
| Q2 2021 | $348,000 | +0.9% | 12,684 | +3.2% | 0.00% | 0.0% |
| Q1 2021 | $345,000 | +70.8% | 12,296 | +57.7% | 0.00% | +100.0% |
| Q4 2020 | $202,000 | +274.1% | 7,797 | +146.9% | 0.00% | – |
| Q3 2020 | $54,000 | +50.0% | 3,158 | +118.7% | 0.00% | – |
| Q2 2020 | $36,000 | – | 1,444 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |